• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Overdiagnosis and overtreatment of early detected prostate cancer.早期检测出的前列腺癌的过度诊断与过度治疗。
World J Urol. 2007 Mar;25(1):3-9. doi: 10.1007/s00345-007-0145-z. Epub 2007 Feb 14.
2
Cancer overdiagnosis and overtreatment.癌症过度诊断和过度治疗。
Curr Opin Urol. 2012 May;22(3):203-9. doi: 10.1097/MOU.0b013e32835259aa.
3
Defining and predicting indolent and low risk prostate cancer.定义和预测惰性和低危前列腺癌。
Crit Rev Oncol Hematol. 2012 Aug;83(2):235-41. doi: 10.1016/j.critrevonc.2011.10.003. Epub 2011 Oct 26.
4
Should prostate-specific antigen screening be offered to asymptomatic men?是否应向无症状男性提供前列腺特异性抗原筛查?
Expert Rev Anticancer Ther. 2010 Jul;10(7):1043-53. doi: 10.1586/era.10.64.
5
Why are a high overdiagnosis probability and a long lead time for prostate cancer screening so important?为什么前列腺癌筛查的高过度诊断概率和长领先时间如此重要?
J Natl Cancer Inst. 2009 Mar 18;101(6):362-3. doi: 10.1093/jnci/djp028. Epub 2009 Mar 10.
6
Prostate cancer overdiagnosis and overtreatment.前列腺癌过度诊断与过度治疗。
Curr Opin Endocrinol Diabetes Obes. 2013 Jun;20(3):204-9. doi: 10.1097/MED.0b013e328360332a.
7
Active surveillance for prostate cancer: a review.前列腺癌的主动监测:综述
Arch Esp Urol. 2011 Oct;64(8):806-14.
8
Overdiagnosis and overtreatment of prostate cancer.前列腺癌的过度诊断与过度治疗。
Eur Urol. 2014 Jun;65(6):1046-55. doi: 10.1016/j.eururo.2013.12.062. Epub 2014 Jan 9.
9
Active surveillance: pitfalls to consider.主动监测:需考虑的陷阱。
Arch Esp Urol. 2011 Oct;64(8):695-702.
10
Predictive models in diagnosing indolent cancer.惰性癌症诊断中的预测模型
Cancer. 2009 Jul 1;115(13 Suppl):3100-6. doi: 10.1002/cncr.24347.

引用本文的文献

1
Key Determinants Influencing Treatment Decision-Making for and Adherence to Active Surveillance for Prostate Cancer: A Systematic Review.影响前列腺癌积极监测治疗决策和依从性的关键决定因素:一项系统综述。
J Pers Med. 2025 Jul 15;15(7):315. doi: 10.3390/jpm15070315.
2
Testing the accuracy of a three-miRNA panel for the detection of primary prostate cancer: a discovery and validation study.检测用于原发性前列腺癌检测的三miRNA检测板的准确性:一项发现与验证研究。
Future Oncol. 2025 Jul;21(17):2167-2176. doi: 10.1080/14796694.2025.2514930. Epub 2025 Jun 6.
3
Prostate cancer nomograms and their application in Asian men: a review.前列腺癌列线图及其在亚洲男性中的应用:综述
Prostate Int. 2024 Mar;12(1):1-9. doi: 10.1016/j.prnil.2023.07.004. Epub 2023 Aug 4.
4
Plasma metabolomics profiling of 580 patients from an Early Detection Research Network prostate cancer cohort.580 名早期检测研究网络前列腺癌队列患者的血浆代谢组学分析。
Sci Data. 2023 Nov 25;10(1):830. doi: 10.1038/s41597-023-02750-7.
5
Unveiling Disrupted Lipid Metabolism in Benign Prostate Hyperplasia, Prostate Cancer, and Metastatic Patients: Insights from a Colombian Nested Case-Control Study.揭示良性前列腺增生、前列腺癌和转移患者中脂质代谢紊乱:来自哥伦比亚巢式病例对照研究的见解
Cancers (Basel). 2023 Nov 18;15(22):5465. doi: 10.3390/cancers15225465.
6
Radiomic-based machine learning model for the accurate prediction of prostate cancer risk stratification.基于放射组学的机器学习模型用于准确预测前列腺癌风险分层。
Br J Radiol. 2023 Mar;96(1143):20220238. doi: 10.1259/bjr.20220238. Epub 2023 Jan 4.
7
Integrated analysis reveals prognostic value and progression-related role of AMIGO2 in prostate cancer.综合分析揭示了AMIGO2在前列腺癌中的预后价值及与进展相关的作用。
Transl Androl Urol. 2022 Jul;11(7):914-928. doi: 10.21037/tau-21-1148.
8
The ReIMAGINE Multimodal Warehouse: Using Artificial Intelligence for Accurate Risk Stratification of Prostate Cancer.重新构想多模式仓库:利用人工智能对前列腺癌进行准确的风险分层。
Front Artif Intell. 2021 Nov 16;4:769582. doi: 10.3389/frai.2021.769582. eCollection 2021.
9
Emerging methods for prostate cancer imaging: evaluating cancer structure and metabolic alterations more clearly.新兴的前列腺癌成像方法:更清晰地评估癌症结构和代谢变化。
Mol Oncol. 2021 Oct;15(10):2565-2579. doi: 10.1002/1878-0261.13071. Epub 2021 Aug 30.
10
Can Prostate-Specific Antigen Density Be an Index to Distinguish Patients Who Can Omit Repeat Prostate Biopsy in Patients with Negative Magnetic Resonance Imaging?前列腺特异性抗原密度能否作为区分磁共振成像阴性患者中可省略重复前列腺活检的患者的指标?
Cancer Manag Res. 2021 Jul 8;13:5467-5475. doi: 10.2147/CMAR.S318404. eCollection 2021.

本文引用的文献

1
hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.人激肽释放酶2(hK2)与游离前列腺特异性抗原(free PSA)联合检测,可预测PSA值在4-10 ng/ml范围内的筛查发现的男性患者是否患有微小前列腺癌,是一种具有预后价值的组合检测方法。
Eur Urol. 2007 Nov;52(5):1358-64. doi: 10.1016/j.eururo.2007.04.037. Epub 2007 Apr 20.
2
Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram.惰性前列腺癌的预测:预后列线图的验证与更新
J Urol. 2007 Jan;177(1):107-12; discussion 112. doi: 10.1016/j.juro.2006.08.068.
3
Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON).筛查试验中基于风险从普通人群中进行选择:荷兰 - 比利时随机肺癌多层CT筛查试验(NELSON)的选择标准、招募及效能
Int J Cancer. 2007 Feb 15;120(4):868-74. doi: 10.1002/ijc.22134.
4
Survival of patients with stage I lung cancer detected on CT screening.CT筛查发现的I期肺癌患者的生存率。
N Engl J Med. 2006 Oct 26;355(17):1763-71. doi: 10.1056/NEJMoa060476.
5
Active surveillance versus radical treatment for favorable-risk localized prostate cancer.低危局限性前列腺癌的主动监测与根治性治疗对比
Curr Treat Options Oncol. 2006 Sep;7(5):355-62. doi: 10.1007/s11864-006-0003-z.
6
Gleason score, age and screening: modeling dedifferentiation in prostate cancer.格里森评分、年龄与筛查:前列腺癌去分化建模
Int J Cancer. 2006 Nov 15;119(10):2366-71. doi: 10.1002/ijc.22158.
7
Prostate specific antigen changes as related to the initial prostate specific antigen: data from the prostate, lung, colorectal and ovarian cancer screening trial.与初始前列腺特异性抗原相关的前列腺特异性抗原变化:来自前列腺、肺、结肠直肠和卵巢癌筛查试验的数据。
J Urol. 2006 Apr;175(4):1286-90; discussion 1290. doi: 10.1016/S0022-5347(05)00706-8.
8
Tumour features in the control and screening arm of a randomized trial of prostate cancer.前列腺癌随机试验对照组和筛查组的肿瘤特征
Eur Urol. 2006 Jul;50(1):70-5. doi: 10.1016/j.eururo.2005.11.005. Epub 2005 Dec 19.
9
The effectiveness of screening for prostate cancer: a nested case-control study.前列腺癌筛查的有效性:一项巢式病例对照研究。
Arch Intern Med. 2006 Jan 9;166(1):38-43. doi: 10.1001/archinte.166.1.38.
10
Use of 2.6 ng/ml prostate specific antigen prompt for biopsy in men older than 60 years.
J Urol. 2005 Dec;174(6):2154-7, discussion 2157. doi: 10.1097/01.ju.0000181213.07447.8f.

早期检测出的前列腺癌的过度诊断与过度治疗。

Overdiagnosis and overtreatment of early detected prostate cancer.

作者信息

Bangma C H, Roemeling S, Schröder F H

机构信息

Department of Urology, Erasmus University Medical Centre, PO Box 2040, 3000 DR Rotterdam, Netherlands.

出版信息

World J Urol. 2007 Mar;25(1):3-9. doi: 10.1007/s00345-007-0145-z. Epub 2007 Feb 14.

DOI:10.1007/s00345-007-0145-z
PMID:17364211
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1913182/
Abstract

Early detection of prostate cancer is associated with the diagnosis of a considerable proportion of cancers that are indolent, and that will hardly ever become symptomatic during lifetime. Such overdiagnosis should be avoided in all forms of screening because of potential adverse psychological and somatic side effects. The main threat of overdiagnosis is overtreatment of indolent disease. Men with prostate cancer that is likely to be indolent may be offered active surveillance. Evaluation of active surveillance studies and validation of new biological parameters for risk assessment are expected.

摘要

前列腺癌的早期检测与相当一部分惰性癌症的诊断相关,这些癌症在一生中几乎不会出现症状。由于潜在的不良心理和躯体副作用,在所有形式的筛查中都应避免这种过度诊断。过度诊断的主要威胁是对惰性疾病的过度治疗。对于可能是惰性的前列腺癌男性患者,可以提供主动监测。预计将对主动监测研究进行评估,并验证用于风险评估的新生物学参数。